Conversely, pharmacological inhibition of SMARCA4 with FHD‐286 promotes NE subtype transform to non‐NE subtype in SCLC, and as well as activating ERBB signaling, therefore, sensitizes to afatinib. This evidence concerns the gene SMARCA4 and small cell lung carcinoma.